Evaluation of the risk factors for the failure of a single prophylactic dose of anticholinergic drugs for irinotecan-induced cholinergic symptoms
Int. Journal of Clinical Pharmacology and Therapeutics · 2024
DOI: 10.5414/cp204531 ↗Kurz gefasst
Fachartikel in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2024. Verfasst von Takuya Watanabe und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Cholinergic Antagonists, Colorectal Neoplasms, Hydrocarbons, Brominated.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Watanabe, T., Saito, Y., Takekuma, Y., Shimizu, Y., Kinoshita, I., Komatsu, Y., & Sugawara, M. (2024). Evaluation of the risk factors for the failure of a single prophylactic dose of anticholinergic drugs for irinotecan-induced cholinergic symptoms. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204531
Vancouver
Watanabe T, Saito Y, Takekuma Y, Shimizu Y, Kinoshita I, Komatsu Y, et al. Evaluation of the risk factors for the failure of a single prophylactic dose of anticholinergic drugs for irinotecan-induced cholinergic symptoms. Int. Journal of Clinical Pharmacology and Therapeutics. 2024. doi:10.5414/cp204531
BibTeX
@article{Watanabe2024,
author = {Watanabe, Takuya and Saito, Yoshitaka and Takekuma, Yoh and Shimizu, Yasushi and Kinoshita, Ichiro and Komatsu, Yoshito and Sugawara, Mitsuru},
title = {Evaluation of the risk factors for the failure of a single prophylactic dose of anticholinergic drugs for irinotecan-induced cholinergic symptoms},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2024},
doi = {10.5414/cp204531}
}
EUVIMED